Clinical Research and Development of Tuberculosis Diagnostics: Moving From Silos to Synergy

Authors

Payam Nahid, University of California, San Francisco
Peter S. Kim, National Institute of Allergy and Infectious Diseases, Bethesda
Carlton A. Evans, Universidad Peruana Cayetano Heredia, Peru
David Alland, University of Medicine and Dentistry of New Jersey, Newark
Michael Barer, University of Leicester, United Kingdom
Jane Diefenbach, PharmaStat LLC, Newark, California
Jerrold Ellner, Boston University School of Medicine and Medical Center, Massachusetts
Richard Hafner, National Institute of Allergy and Infectious Diseases, Bethesda
Carol Dukes Hamilton, 8Family Health International, Durham, North Carolina
Michael F. Iademarco, Centers for Disease Control and Prevention, Atlanta, Georgia
Gregory Ireton, Infectious Disease Research Institute, Seattle, Washington
Michael E. Kimerling, Global Health Program, Bill & Melinda Gates Foundation, Seattle, Washington
Christian Lienhardt, World Health Organization, Geneva, Switzerland
William R. MacKenzie, Centers for Disease Control and Prevention, Atlanta, Georgia
Megan Murray, Harvard School of Public Health, Boston, Massachusetts
Mark D. Perkins, Foundation for Innovative New Diagnostics, Geneva, Switzerland
Jamie E. Posey, Centers for Disease Control and Prevention, Atlanta, Georgia
Teri Roberts, Me´dicins San Frontie`res, Geneva, Switzerland
Christine Sizemore, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
Wendy S. Stevens, University of Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa
Laura Via, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
Sharon D. Williams, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
Wing Yew, Chest and Heart Diseases Association, China
Susan Swindells, University of Nebraska Medical CenterFollow

Date of this Version

2012

Citation

Clinical R&D of Tuberculosis Diagnostics JID 2012:205 (Suppl 2) S159

DOI: 10.1093

Abstract

The development, evaluation, and implementation of new and improved diagnostics have been identified as critical needs by human immunodeficiency virus (HIV) and tuberculosis researchers and clinicians alike. These needs exist in international and domestic settings and in adult and pediatric populations. Experts in tuberculosis and HIV care, researchers, healthcare providers, public health experts, and industry representatives, as well as representatives of pertinent US federal agencies (Centers for Disease Control and Prevention, Food and Drug Administration, National Institutes of Health, United States Agency for International Development) assembled at a workshop proposed by the Diagnostics Working Group of the Federal Tuberculosis Taskforce to review the state of tuberculosis diagnostics development in adult and pediatric populations.